Skip to main content
SpringerLink
Log in

Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Atrial fibrillation, the most common cardiac arrhythmia in clinical practice, causes significant burden to patients and health care systems worldwide. Attention is being paid to prevention of atrial fibrillation using drugs that retard or prevent atrial.brosis and arrhythmogenic remodeling, which lead to this arrhythmia. Agents that work through the renin-angiotensin-receptor system, the angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, are showing promise in animal and human studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N-9N.

    Article  PubMed  CAS  Google Scholar 

  2. Thom T, Haase N, Rosamond W, et al.: Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151.

    Article  PubMed  Google Scholar 

  3. Wu EQ, Birnbaum HG, Mareva M, et al.: Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005, 21:1693–1699.

    Article  PubMed  Google Scholar 

  4. Benjamin EJ, Levy D, Vaziri SM, et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840–844.

    Article  PubMed  CAS  Google Scholar 

  5. Djoussé L, Levy D, Benjamin EJ, et al.: Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol 2004, 93:710–713.

    Article  PubMed  CAS  Google Scholar 

  6. Wachtell K, Lehto M, Gerdts E, et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712–719.

    Article  PubMed  CAS  Google Scholar 

  7. Humphries KH, Kerr CR, Connolly SJ, et al.: New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001, 103:2365–2370.

    PubMed  CAS  Google Scholar 

  8. Eaker ED, Sullivan LM, Kelly-Hayes M, et al.: Does job strain increase the risk for coronary heart disease or death in men and women? The Framingham Offspring Study. Am J Epidemiol 2004, 159:950–958.

    Article  PubMed  Google Scholar 

  9. Eaker ED, Sullivan LM, Kelly-Hayes M, et al.: Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med 2005, 67:692–696.

    Article  PubMed  Google Scholar 

  10. Camm AJ, Obel OA: Epidemiology and mechanism of atrial fibrillation and atrial.utter. Am J Cardiol 1996, 78:3–11.

    Article  PubMed  CAS  Google Scholar 

  11. Okcun B, Yigit Z, Kucukoglu MS, et al.: Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. Echocardiography 2002, 19:351–357.

    Article  PubMed  Google Scholar 

  12. Gensini F, Padeletti L, Fatini G, et al.: Angiotensinconverting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003, 26:295–298.

    Article  PubMed  Google Scholar 

  13. Tsai CT, Lai LP, Lin JL, et al.: Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004, 109:1640–1646.

    Article  PubMed  CAS  Google Scholar 

  14. Bradley D, Creswell LL, Hogue CW, Jr, et al.: Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005, 128:39S-47S.

    Article  PubMed  CAS  Google Scholar 

  15. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999, 82:170–175.

    PubMed  CAS  Google Scholar 

  16. Psaty BM, Manolio TA, Kuller LH, et al.: Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997, 96:2455–2461.

    PubMed  CAS  Google Scholar 

  17. Kuhlkamp V, Schirdewan A, Stangl K, et al.: Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized, doubleblind, placebo-controlled study. J Am Coll Cardiol 2000, 36:139–146.

    Article  PubMed  CAS  Google Scholar 

  18. Wachtell K, Hornestam B, Lehto M, et al.: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:705–711.

    Article  PubMed  Google Scholar 

  19. Goette A, Arndt M, Rocken C, et al.: Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000, 101:2678–2681.

    PubMed  CAS  Google Scholar 

  20. Goette A, Staack T, Rocken C, et al.: Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000, 35:1669–1677.

    Article  PubMed  CAS  Google Scholar 

  21. Okin PM, Devereux RB, Jern S, et al.: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004, 292:2343–2349.

    Article  PubMed  CAS  Google Scholar 

  22. Fogari R, Mugellini A, Destro M, et al.: Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006, 47:46–50.

    Article  PubMed  CAS  Google Scholar 

  23. Li D, Shinagawa K, Pang L, et al.: Effects of angiotensinconverting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001, 104:2608–2614.

    PubMed  CAS  Google Scholar 

  24. Shi Y, Li D, Tardif JC, Nattel S: Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002, 54:456–461.

    Article  PubMed  CAS  Google Scholar 

  25. Nakashima H, Kumagai K, Urata H, et al.: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000, 101:2612–2617.

    PubMed  CAS  Google Scholar 

  26. Kumagai K, Nakashima H, Urata H, et al.: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003, 41:2197–2204.

    Article  PubMed  CAS  Google Scholar 

  27. Klein HU, Goette A: Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 2003, 41:2205–2206.

    Article  PubMed  Google Scholar 

  28. Schiffrin EL: Vascular and cardiac bene.ts of angiotensin receptor blockers. Am J Med 2002, 113:409–418.

    Article  PubMed  CAS  Google Scholar 

  29. Madrid AH, Peng J, Zamora J, et al.: The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004, 27:1405–1410.

    Article  PubMed  Google Scholar 

  30. Healey JS, Baranchuk A, Crystal E, et al.: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005, 45:1832–1839. This article presents the results of a meta-analysis of 11 clinical trials evaluating RAAS agents for primary prevention of AF. The plots of the risk reductions by study and by patient population are helpful.

    Article  PubMed  CAS  Google Scholar 

  31. Teo K, Yusuf S, Sleight P, et al.: Rationale, design and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Rampril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 2004, 148:52–61.

    Article  PubMed  CAS  Google Scholar 

  32. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C:Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376–380.

    PubMed  CAS  Google Scholar 

  33. Vermes E, Tardif JC, Bourassa MG, et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926–2931.

    Article  PubMed  Google Scholar 

  34. L’Allier PL, Ducharme A, Keller PF, et al.: Angiotensinconverting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004, 44:159–164.

    Article  PubMed  CAS  Google Scholar 

  35. Ueng KC, Tsai TP, Yu WC, et al.: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003, 24:2090–2098.

    Article  PubMed  CAS  Google Scholar 

  36. Salehian O, Healey J, Almerri, et al.: Neither ramipril nor vitamin E reduce the incidence of atrial fibrillation. Results of the HOPE study [abstract]. J Am Coll Cardiol 2006, 47(Suppl A):8A-9A.

    Google Scholar 

  37. Madrid AH, Bueno MG, Rebollo JM, et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331–336.

    Article  PubMed  CAS  Google Scholar 

  38. Maggioni AP, Latini R, Carson PE, et al.: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005, 149:548–557.

    Article  PubMed  CAS  Google Scholar 

  39. Gerdts E, Oikarinen L, Palmieri V, et al.: Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002, 39:739–743.

    Article  PubMed  CAS  Google Scholar 

  40. Benjamin EJ, D’Agostino RB, Belanger AJ, et al.: Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995, 92:835–841.

    PubMed  CAS  Google Scholar 

  41. Gottdiener JS, Reda DJ, Williams DW, et al.: Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1998, 98:140–148.

    PubMed  CAS  Google Scholar 

  42. Devereux RB, Dahlöf B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  43. Okin PM, Devereux RB, Jern S, et al.: Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003, 108:684–690.

    Article  PubMed  CAS  Google Scholar 

  44. Gerdts E, Wachtell K, Omvik, P, et al.: Left atrial size and risk of major cardiovascular events in hypertensive patients with left ventricular hypertrophy (the LIFE study) [abstract]. Circulation 2003, 108:IV371.

    Google Scholar 

  45. Wachtell K, Gerdts E, Aurigemma G, et al.: Does reduction in left atrial diameter during antihypertensive treatment reduce new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the LIFE study [abstract]. J Am Coll Cardiol 2006, 47:9A.

    Google Scholar 

  46. Lindholm LH, Dahlöf B, Edelman JM, et al.: Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003, 362:619–620.

    Article  PubMed  CAS  Google Scholar 

  47. Madrid AH, Marin IM, Cervantes CE, et al.: Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004, 5:114–120.

    Article  PubMed  CAS  Google Scholar 

  48. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231–1266.

    Article  PubMed  CAS  Google Scholar 

  49. Verma A, Natale A: Should atrial fibrillation ablation be considered.rst-line therapy for some patients? Why atrial fibrillation ablation should be considered.rst-line therapy for some patients. Circulation 2005, 112:1214–1222.

    Article  PubMed  Google Scholar 

  50. Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide,.ecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781–788.

    Article  PubMed  CAS  Google Scholar 

  51. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992, 327:227–233.

    Article  Google Scholar 

  52. Waldo AL, Camm AJ, deRuyter H, et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996, 348:7–12.

    Article  PubMed  CAS  Google Scholar 

  53. AFFIRM First Antiarrhythmic Drug Substudy Investigators: Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the.rst antiarrhythmic drug.J Am Coll Cardiol 2003, 42:20–29.

    Article  Google Scholar 

  54. Hohnloser SH, Connolly SJ: Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003, 14:S60-S63.

    Article  PubMed  Google Scholar 

  55. Arima H, Hart RG, Colman S, et al.: Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005, 36:2164–2169.

    Article  PubMed  CAS  Google Scholar 

  56. Cifkova R, Erdine S, Fagard R, et al.: Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003, 21:1779–1786.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rigshospitalet, Department of Cardiology B2142, The Heart Center, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark

    Kristian Wachtell MD, PhD

Authors
  1. Kristian Wachtell MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard B. Devereux MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paulette A. Lyle BS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristian Wachtell MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wachtell, K., Devereux, R.B. & Lyle, P.A. Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. Curr Cardiol Rep 8, 356–364 (2006). https://doi.org/10.1007/s11886-006-0075-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-006-0075-1

Keywords

Search

Navigation